Free to Attend | April 7, 2025 | 1:30 PM PT
The Next Standard of Care in Open Heart Surgery
Join our leadership for a live pitch deck presentation and Q&A with investors. This is the hour to understand what your capital funds and what the upside looks like at this stage of the company.
The Problem
Cardiac Surgery's Billion-Dollar Complication
1.8 million Americans have open-heart surgery every year. Half of them develop a complication called post-operative atrial fibrillation — POAF — before they ever leave the hospital. It doubles their risk of death. It quadruples their stroke risk. It can add a week to an ICU stay.
There is no approved preventive treatment. None. No drugs work. Every surgeon in the field knows this. It has been known for decades. And nothing has changed.
This gap in treatment costs the US healthcare system $9+ billion a year. It can cost patients their lives. BioXgen is the result of 14 years of focused effort to close that gap.
The Solution
A MedTech Breakthrough for Open Heart Surgeries
BioXgen's ECM patch is placed on the heart during surgery. It tells the body to heal instead of scar.
In clinical use, POAF rates have dropped from 50% to under 5%. The safety record behind ECM technology spans 80+ years.
BioXgen has 14 years of its own cardiac research and 51 treated patients behind this specific application.
Meet the Hosts
Dr. David Skinner, MD, PhD, MBA
President & CEO
Dr. Skinner built a medical company from 5 employees to 156, across nine locations, and took it to a successful private equity exit. He holds a combined MD/PhD from the University of Arizona — finished in five years, with the Outstanding Achievement Award — and an MBA from the W.P. Carey School of Business. He built BioXgen because he recognized that a product working in the lab had never been built into something the market could actually absorb at scale. He is fixing that.
Dr. John P. Konhilas, PhD
Chief Science Officer
Dr. Konhilas spent 30 years as a professor of physiology building translational research programs aimed at real cardiac outcomes. He holds 11 patents, has a recent IND approval for clinical research, and co-founded Menolabs — acquired in 2022. He also brings something most scientists at his level don't: a track record of identifying underserved medical markets, building companies around them, and seeing them through to acquisition.
Don't Miss our live investor presentation with the founders
Get insights into our pathway to 510(k) FDA-clearance and get your questions answered!